Tetraphase has two suit­ors, de­spite strug­gling mar­ket for an­tibi­otics

The mar­ket for an­tibi­otics may be “bro­ken,” but one small an­tibi­ot­ic com­pa­ny is seem­ing­ly in de­mand: Tetraphase Phar­ma­ceu­ti­cals. In March, the com­pa­ny said it had agreed to be ac­quired by Acel­Rx in an all-stock deal val­ued at $14.4 mil­lion. But this week, an­oth­er drug­mak­er ap­pears to be court­ing Tetraphase — La Jol­la Phar­ma­ceu­ti­cals sub­mit­ted a non-bind­ing pro­pos­al to swal­low Tetraphase for $22 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER